Similar combinations of NP-1 and amphotericin B, however, did not yield synergy.

Only amphotericin B was statistically superior to controls with regard to mortality.

However, data on agar-based tests for itraconazole and amphotericin B are yet scarce.

Treatment consisted in systemic amphotericin B combined with surgical debridement in 3 cases.

Large doses of amphotericin B are required for cure, causing significant renal toxicity.

The patient progressively lost vision despite amphotericin B and 5-fluorocytosine therapy.

Susceptibility testing confirmed the broad activity of amphotericin B and echinocandins.

Amphotericin B concentrations were measured using HPLC after purification by solid phase extraction.

Therapy for these mycoses relies on the use of amphotericin B and 5-fluorocytosine.

The patients was treated with amphotericin B with regression of the skin lesions.

However, breakthrough fungal infections can develop despite treatment, and amphotericin B has substantial toxicity.

Itraconazole offers a new oral alternative to conventional amphotericin B therapy in these infections.

Conclusions: The choice of lipid formulation may influence amphotericin B penetration into the lung.

High-dose liposomal amphotericin B was effective and safe in the treatment of neonatal candidiasis.

All patients were treated with amphotericin B with or without flucytosine as initial therapy.

Amphotericin B is an essential medicine for treating this illness.